ISRCTN92152389CompletedNot Applicable
A clinical feasibility study to evaluate the effectiveness and safety of VivescOs™ as bone graft for reconstruction of intra-oral osseous defects
IsoTis NV (The Netherlands)0 sites10 target enrollmentStarted: September 26, 2006Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Repair of the intra-oral defect was indicated as preparation for dental implant placement in a secondary stage.
Exclusion Criteria
- •1. Presence of local or systemic disease;
- •2. Pregnancy, cancertherapy;
- •3. Previous participation in another trial within 30 days;
- •4. Known hypersensitivity for penicillin, streptomycin.
Investigators
Similar Trials
Completed
Not Applicable
A clinical feasibility study to evaluate the effectiviness and safety of VivescOs TM as bone graft for reconstruction of intra-oral osseous defects.NL-OMON24005Isotis, Bilthoven, the Netherlands10
Completed
Not Applicable
Feasibility study to evaluate the clinical outcome of the Scorpio knee prosthesis following THE LAZIRUSH CONCEPTKnee arthrosis10023213NL-OMON34366Stryker SA50
Recruiting
Not Applicable
The clinical effectiveness of EMDR second-step intervention for non-responders to CBT for Panic Disorder with or without Agoraphobia: an uncontrolled pilot study.Panic disorderNL-OMON26887HSK, University of Utrecht15
Completed
Not Applicable
A feasibility study to evaluate the efficacy and safety of endoscopic ultrasound-guided through-the-needle pancreatic cyst wall biopsyPancreatic cystic neoplasmJPRN-UMIN000016311Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine22
Completed
Not Applicable
A prospective clinical study to evaluate the feasibility and safeness of the chemotherapy with weekly paclitaxel administration in cases with anaplastic thyroid cancerJPRN-UMIN000008574Anaplastic Thyroid Carcinoma Consortium Japan50